What is the effect of cycloadenosine meglumine for injection

Worldwide, one person dies from heart disease every minute.

(2) Heart failure, myocarditis, sick sinus syndrome, coronary heart disease, arrhythmia, cardiovascular medicine intravenous drip: add 200-500ml 5% glucose injection solution to dissolve and then intravenously drip, once a day, 60-180mg each time; 2. Intravenous push: add 20-40 ml of 25% or 10% glucose injection solution to dissolve and slowly push intravenously, once a day, 90 mg each time.

4 Adverse reactions

Occasionally, symptoms such as palpitations, heart palpitations, and dizziness may occur. 5 Precautions (1) Do not infuse too quickly. Doses above 150 mg should be infused over 90 minutes.

(2) If you experience palpitations or nausea during the infusion, you should stop taking the medication. The symptoms will disappear on their own after stopping the medication.

(3) The drug is prohibited from use when its properties change. 6 Pharmacology and Toxicology This product has a non-digitalis positive inotropic effect, which can increase myocardial contractility and improve cardiac pumping function; it has a vasodilator effect, which can reduce myocardial oxygen consumption; it improves myocardial cell metabolism, protects ischemic and hypoxic myocardium; and can improve the function of sinoatrial node P cells. Pharmacokinetics: Cyclic adenosine phosphate meglumine enters the human body with a half-life of 60 to 150 minutes in the blood. Due to its good hydrophilicity, especially its strong lipid solubility, it can easily penetrate lipid-soluble cell membranes into myocardial cells to exert its effects. It is decomposed into 5-AMP by phosphodiesterase, and then degraded into adenosine and phosphate by 5-AMP. Cyclic adenosine phosphate meglumine begins to work 10 to 20 minutes after administration, with the peak effect time being 1 to 2 hours and the drug effect disappearing time being 6 to 8 hours.